

## ASX Release

---

# ANAGRELIDE PROJECT UPDATE

**PERTH, AUSTRALIA – 26 February 2021:** SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, advises that SUDA has contracted the services of MedPharm, who will perform formulation development work to assist in stabilising and optimising the oral spray formulation for anagrelide.

MedPharm is a world-leading Contract Development and Manufacturing Organisation (CDMO) that focus on topical and transdermal product design and development services.

SUDA's CEO and MD, Dr Michael Baker, commented: "We are excited to be working with MedPharm on the anagrelide project. MedPharm has an excellent reputation for the development of transdermal products and we look forward to working together."

For and on behalf of the Board and for further information please contact:

**Dr Michael Baker**

**Chief Executive Officer & Managing Director**

**SUDA Pharmaceuticals Ltd**

Tel +61 (0) 403 468 187

mbaker@sudapharma.com

## **NOTES TO EDITORS:**

### **About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem tartrate for the treatment of short-term insomnia. ZolpiMist is approved by the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of migraine headache, motion sickness, drug resistant epilepsy and certain cancers.

For more information, visit [www.sudapharma.com](http://www.sudapharma.com)

### **About MedPharm**

MedPharm is the world's leading contract provider of topical and transdermal product design and formulation development services. MedPharm expertly reduces risk and accelerates development times for generic and proprietary pharmaceutical customers through its unique, cost-effective, and industry-leading [performance testing models](#). Well established as the global leaders in [dermatology, nail, mucosal membrane, and transdermal](#) product development, MedPharm can also offer innovative solutions for [ophthalmic and airway preparations](#) recognised for their scientific rigour by regulators and investors. MedPharm has fully established Centers of Excellence in the USA and the UK.

For more information, visit [www.medpharm.com/development-philosophy](http://www.medpharm.com/development-philosophy)